Nov. 9 (UPI) — On Monday, the U.S. Food and Drug Administration announced new safety labeling for glucagon-like peptide-1 receptor agonist medications such as Zepbound and Wegovy, warning of a potential increased risk for a rare eye condition.

GLP-1 RA medications mimic the effects of the natural hormone glucagon-like peptide-1 released by the intestines. The hormone helps control blood sugar levels after eating and acts in parts of the brain that control appetite and eating, the FDA said.

These medications are used to treat people with type 2 diabetes and for weight control purposes. They are also used for other reasons such as reducing the risk of major cardiovascular events.

However, the FDA said Monday that the medications can cause a potential increased risk for non-arteritic anterior ischemic optic neuropathy, or NAION. This is a rare eye condition that can cause decreased vision in one eye, sometimes leading to permanent vision loss.

The FDA is requiring companies that produce GLP-1 RA medications to include labeling warning people of this risk, it said.

FDA-approved GLP-1 RA medications include those sold under the names Byetta, Victoza, Trulicity, Saxenda, Xultophy, Soliqua, Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound and Foundayo.

Associated generic names include exenatide, liraglutide, dulaglutide, liraglutide plus insulin degludec, lixisenatide plus insulin glargine, semaglutide, tirzepatide and orforglipron.

Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking; blurred or missing portions of vision (such as blind spots or tunnel vision); distortion of colors; and reduced central sharpness of vision. Those experiencing these symptoms should contact their healthcare professional.

NAION is caused by decreased blood flow to the front part of the optic nerve. Risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease.